T here have been many attempts to define the benefit of SDD with varying degrees of success. A review by Amico and Pifferi 1 showed both a reduction in the incidence and mortality from respiratory tract infection in patients treated with SDD. A review of 17 trials2 in which topical agents had been used alone failed to demonstrate a reduction in mortality although it did show a reduction in respiratory tract infections. Survivors appeared to have an overrepresentation from surgical and trauma patients even though trials looking at the use of SDD in specific surgical conditions were excluded from the meta-analysis. A further review concluded that SDD reduced mortality in critically ill surgical and trauma patients but not in critically ill medical patients. There was however no standardization of SDD regimes and definitions, making results difficult to interpret.
The possibility of multiresistant bacteria in association with SDD therapy has been considered in a number of publications. Gustine et al noted a higher incidence of Staphylococcal pneumonia associated with SDD. Other investigators have noted occurrence of other pneumonias perhaps in association with SDD2,3. This is illustrated by Bonten et al2 who after recruiting 61 patients to a topical SDD regime without systemic antibiotics, noted that 24 became colonized with E. Faecalis and from which 8 developed pneumonia and/or bacteraemia.
Sanchez-Garcia et al4 reported a reduction in frequency of nosocomial pneumonia with the use of SDD but also a concomitant increase in carriage of methicillin-resistant staphylococcus aureus (MRSA), coagulasenegative staphylococci, and enterococcus in patients receiving such therapy.
Abstract
A randomized un-blinded controlled trial of 934 patients admitted to a surgical and a medical ITU comparing standard care to a SDD treatment group of oral and enteral polymixin E, tobramycin, and amphotericin B in addition to a 4-day course of IV cefotaxime. The study showed a reduction in mortality in the SDD group vs. control (24% vs. 31%). Both medical and surgical patients showed a reduced mortality. Median length of stay in ICU was shorter in the SDD group by 1.7 days and antibiotic usage was reduced such that it more than offset the cost of the SDD agents.
Importantly colonization with vancomycinresistant enterococcus occurred with the same frequency in SSD and control groups and neither group was colonized with MRSA.
Are the results of the study valid?
Primary Guides
Was the assignment of patients to treatments randomised? Were all patients who entered the trial accounted for at its conclusion?
The patients in this study were randomised to either standard treatment or enteral polymyxin E, tobramycin and amphoteracin B combined with an initial 4-day course of IV cefotaxime. Nurses independent of the study performed the randomisation. This investigation was conducted in a two-unit institution and one was assigned the duties of looking after the 'standard care' (control) patients and the other the SDD group. Whilst this might lead to differences in the care provided to patients, the authors have explained its necessity on the basis of "preventing cross-colonisation between SDD patients and controls".
Of 1090 patients who met study inclusion criteria, 934 patients entered the study and were included in the results. The remainder declined inclusion or were unable to give consent. Selective cultures were available at baseline for 868 of those patients and 773 at follow up.
Aside from the experimental treatment, were the groups treated equally?
Were the groups similar at the start of the trial?
Because of the nature of the treatment and the randomisation, it Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised trial.
Introduction

Selective digestive decontamination (SDD) regimes often use a combination of topical anti-bacterial and antifungal agents applied to accessible parts of the digestive tract, which may be given with a short course of systemic, broad-spectrum antibiotic. It has been suggested that the decrease in 'bacterial load 'in the GIT that this causes can decrease the incidence of predominantly gramnegative sepsis that occurs in critically ill patients. A concern with
this approach is that manipulation of the microbiological environment may increase the incidence of multi-resistant infections Demographically, in terms of disease severity and co-morbidity the two groups were similar.
The isolation of the two units may be a deficiency in that staff were confined exclusively to either one unit or the other and this might lead to a loss of uniformity in the care.
If analysis has been done and conclusions made:
Do they really make biologic and clinical sense?
The results are in keeping with theories suggesting that GIT colonization is associated with nosocomial infection and sepsis on the ITU as have been previously alluded to in this article.
Is the qualitative difference both clinically and statistically significant?
The results do appear to be statistically significant and have clear clinical benefit in terms of reduced ICU stay, in hospital mortality and total costs of antibiotic treatment.
3. Was this difference hypothesised before the study began (rather than the product of dredging the data) and has it been confirmed in other, independent studies? Significant controversy has existed over the benefit of SDD on mortality and antibiotic resistance, as previous trial outcomes have been inconsistent and conflicting. The predetermined primary end points of this study were mortality and acquisition of resistant bacteria.
Are the valid results of this trial important?
• • Number needed to treat for prophylaxis to prevent an ICU death was 13 and to prevent a hospital death was 14 • The NNT to prevent colonisation with gram negative bacteria resistant to ceftazidime, ciprofloxacin, imipenem, polymyxin E or tobramycin was 10
Conclusion
This latest trial supports the use of SDD and goes some way towards addressing some of the fears that arose from previous studies. It is important to stress that the units had a 0% incidence of MRSA. This, in our experience, is not representative of ICU in the UK and makes it difficult to advocate implementation of this practice. It will remain for individual institutions to decide their position on this issue but views are going to be tempered by concerns over the development of multi-resistant organisms. !
